

**Request under Freedom of Information Act 2000**

Thank you for your request for information which we received on Monday 8<sup>th</sup> July 2024. I am pleased to confirm the following.

**Q1. In the last 6 months, how many patients have been diagnosed with Diffuse Large B Cell Lymphoma (DLBCL)?**

This information is not available

**Q1a. Of these patients, how many commenced treatments at your trust within the last 6 months?**

This information is not available

**Q2. In the last 6 months, how many patients have you treated for Diffuse Large B Cell Lymphoma (DLBCL) with the following treatments:**

R-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone)-6  
R-mini-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone)-0  
Pola-BR (polatuzumab vedotin with rituximab and bendamustine)-1  
Pola-R-CHP (Polatuzumab vedotin with rituximab, cyclophosphamide, doxorubicin hydrochloride, and prednisolone)- 9  
R-CODOX-M (rituximab, cyclophosphamide, vincristine, doxorubicin and methotrexate)-0  
R-IVAC (rituximab, ifosfamide, etoposide and cytarabine)- 1  
Axicabtagene ciloleucel (Yescarta)  
Tisagenlecleucel  
Epcoritamab- 1  
Loncastuximab tesirine- 1  
Glofitamab-0  
Any other SACT- ibrutinib (1)  
Stem cell transplant or bone marrow transplant (autologous or allogeneic)-

**Q3. In the last 6 months, how many patients have received the following 2nd line treatments for Diffuse Large B Cell Lymphoma (DLBCL):**

Axicabtagene ciloleucel (Yescarta)  
Tisagenlecleucel  
Pola-BR (polatuzumab vedotin with rituximab and bendamustine)- 1  
Stem cell transplant or bone marrow transplant (autologous or allogeneic)-

This information is not available  
Any other treatments

**Q4. In the last 6 months, how many patients have you referred to other trusts for the treatment of Diffuse Large B Cell Lymphoma (DLBCL) for the following treatments:**

CAR-T Therapy (E.g. Axicabtagene ciloleucel)- data not available to pharmacy  
Stem cell transplant or bone marrow transplant (autologous or allogeneic)-

This information is not available

Any other treatment

Please be advised that this information is provided in accordance with the Freedom of Information Act 2000 and is for your personal use. Any re-use of this information will be subject to copyright and the Re-Use of Public Sector Information Regulations (1st July 05) and authorisation from Milton Keynes Hospital NHS Foundation Trust will be required. In the event of any re-use, the information must be reproduced accurately and not used in a misleading manner.

If you are unhappy with the information received in response to this request, please address your complaint to the Patient Affairs Office at Milton Keynes Hospital NHS Foundation Trust, Standing Way, Eaglestone, Milton Keynes MK6 5LD. If, after exhausting our internal process, you are still unhappy with the information received, you may write to the Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire SK9 5AF.

If you need any further assistance, please do not hesitate to contact us at the address above.

Yours sincerely

Freedom of Information Co-ordinator  
For and on behalf of Milton Keynes Hospital NHS Foundation Trust

Any re-use of this information will be subject to the  
'Re-use of Public Sector Information Regulations' and best practice.